Member Info for Aqc888

Essentially Kromeks story sounds too good to be true.

They seem to have a great product that has huge potential in terms of government orders. However it’s got echos of an Elizabeth Holmes repeat. The share price seems to cheap for what IP is on offer, and the story of its products seem to good to be true - a solution to the one of the world’s greatest problems. But little of the worlds media, which report constantly on every detail of the pandemic, constantly, seem bothered enough to barely report Kromek.

It feels like a trap. Why aren’t there any institutional investors catching on? Why does Simon Thompson with his track record, on the other hand like it. Where’s that data from the independent accreditation? But on the other hand the Institute of Physics and Cambridge biological expert are singing its praises and DARPA keep giving them funding.

Kromek is a riddle, which is what makes it such an interesting company to watch for so many of us. It’s share price is amongst the most volatile with x4 massive price swings in the past two years. Nobody really knows what’s going on here for sure.

After much swaying and research I’m increasingly confident Kromek will be a good investment over the next year. My investment here is up 10%. But the huge volatility makes it difficult to hold onto when the price surges, you just know it’s a fairly frothy gain and best to sell when it does surge.

Kromek needs to prove they can generate sustained profits, and have exciting IP on top, to get serious long term investors on board.

Excellent article. A fantastic find Vascular.
“Aquire at least three technologies”... that would almost guarantee Kromek has a role. DARPA have only funded four companies to date. One of which is far behind as a previous article I posted reported. Kromek having x2 offices and factories in the us should also help their offering.

Interesting that Kromek trademarked the name of their detector ‘KAPscan’ in the US a short while ago. Looking very promising indeed. All the signs seem to point to a remarkable interim results update on Jan 18th.

Looking back on Jan 19th many of us might wonder why, after seeing all the signals, we weren’t more heavily invested.

Ironknut, I don’t think the people selling today know anything new that we don’t. I’d expect a bit of volatility coming up to results. All that matters in the next few weeks/months is the interim results on Jan18th and the update on the biological pathogen detector. Till then it’s all speculation and emotion driven. I certainly wouldn’t want to be out now. The value of the IP around the biological pathogen detector is zero. Any news here will have a dramatic effect on Kromeks share price.

Telegraphs questor has singled out a healthcare stock as they see this as a growth market in 2022, good for Kromeks CZT scanners.

The great stock market mystery of the past two years in Questor’s view is this: just when the world has been obsessed with fighting disease like never before, healthcare stocks have underperformed the market as a whole.

“The Nasdaq Healthcare index, probably the sector’s best barometer, has risen by 57pc since the depths of the coronavirus sell-off in March 2020. The Nasdaq as a whole has gained 126pc – more than twice as much. Healthcare stocks have gone roughly nowhere over the past year whereas the broader market has continued its strong recovery from that March 2020 nadir.

Let’s therefore regard investors’ current preference for other sectors as a buying opportunity: we will make our stock tip of the year a healthcare company.“

Interesting to see that it’s the director with the most experience in and hired to drive commercialisation that has been buying the most shares.

Strategic investo, we’ve heard in that article they’ve been in talks with Dubai and they’ve had funding from US and U.K. governments, so would guess they’ve had talks with them.

On a flight home to London yesterday there were at least x6 people on connecting flights from the Far East in full hazmat suits with goggles and rubber gloves etc. It’s a stark difference in attitude to here in Europe. Small wealthy countries with high amount of foreigners vusiting, such as Singapore, Dubai must be the most likely clients of this new technology. But we’ll find out in 2weeks now...

Good to see the new chairman has bought 469,000 since he joined Kromek just over a year ago. Looking forward to the interim results on 18th Jan. Surely there’ll be news on the biological pathogen detector...

So I see Kromek more like Kuwait- a little country with a huge discovery and ability to get outside experts to extract most of the value, either through a takeover or by outsourcing. Whereas you see Kromek more of a Venezuela, where they will somehow they’ll manage to destroy all value from their huge IP discovery. I’m increasingly looking forward to 18th Jan

Skid35, to use an analogy, if Kromek were a country it would be a little country that was just on the verge of announcing huge oil reserves discovered underneath it.
Whilst you think they are guaranteed to mess it up, I think that to mess this up like you suggest would take a huge amount of skill to destroy this much value.
Kromek has an experienced chairman at commercialisation and the ability to outsource the manufacturing/servicing. Somehow this huge value of Kromeks IP will ooze out.

Skid, you’re right to see the appointment of the new chairman as a positive. You’d also be aware that the board of directors appointed him because of his experience - and therefore you’d think they’d be taking his advice. The fact the chairman recently purchased Kromek shares will also be an indication he’s happy with his appointment and Kromeks direction. I think his contribution here will be extremely valuable and at the heart of Kromeks commercialisation.

There will be corporations tussling to win any installation/support contracts from Kromek with regards to the detector. Kromek may wish to do it themselves or outsource this like many other companies do.

As a long term holder of Kromek I think you’re not seeing the wood through for the trees on this. This innovation Kromek appear to have their hands on with significant IP, and competitive advantage in terms of time spent developing it (2yrs before pandemic started). It’s this that will push Kromek potentially up to £2 with just one government contract, let alone a few... (ceo claimed they were in serious talks with MULTIPLE governments). The details of who will install and service the devices is the minutiae of what’s on offer here. Good to have your opposing views here, but I can’t see your criticism in regards to this as valid.

Skid35, the detector production has been outsourced for manufacturing. The newly appointed chairman has 20 years' experience in running international hi-tech engineering and manufacturing businesses. I think you’re being a bit over pessimistic here. There’s a clear difference of views on the future outlook of Kromek between old and new holders. The past is not always a reliable guide to the future- especially in respect to Kromek.

Kromek has a lot in common with Xaar, a company with a lot of potentially valuable IP, which reached lows of 20p early 2020 before surging to highs of 260p. With a bit of help from Simon Thompson adding it to his 2020 bargain share list. I see the strong possibility of a similar story with Kromek, it’s got a lot of IP that people aren’t sure how to value. When the value of that IP becomes clearer at the 18th jan interim results (conveniently 2weeks before Simon Thompson’s 2022 bargain share list, coincidental?) I think this has a real possibility of surging. Whilst it will be very tempting to sell at 30p at this stage, I feel that would be a big mistake. Kromek in this scenario will have a long way further to run.

Any negotiations with governments will be bound to have been speed up by omicron. Any politicians who needed swaying over the detectors and had the idea that crossing their fingers will be enough till it’s all over will have had to concede. To not spend the money with the on going risks would be crazy. In defence terms £1.5bn is not much.

Getting increasingly excited by update on jan 18th

I think there’ll be slightly better results than the market expects in jan, I think there’ll be some positive news of some kind regarding the detector and I think Simon Thompson’s inclusion of Kromek in his feb bargain shares edition. If these three predictions come true I can’t see Kromek being below 40p come mid February

My main concern with Kromek is the lack of ownership by the management and institutional investors.

Personally I see previous failures and disappointments as an opportunity to buy at low bargain prices. If this technology is as good as we hope - and the biological warfare specialist and Institute of Physics suggest (with a great deal of IP) then sales should look after themselves. Manufacturing is outsourced.

An area never explored by anyone in this chat room is how good their hospital CZT scanners are compared to the company that was recently sold to Canon. I’d be interested to know more about this.

The reason the share price has performed so badly without ever making a profit is the huge amount they have spent developing IP. Which as new shareholders we’re getting at low low prices. If Kromek had some Steve Jobs type character investing in IP whilst making losses they could probably get away with it. But they’ve got a skilled physicist who’s new to being a ceo and has undoubtedly been on a learning curve whilst not exciting the market sufficiently.

My view of Kromek is that they’ve developed these detectors and they will work. Kromeks poor history means one can buy Kromek at a low price. They can’t mess up sales of the detector if it works to much. There will be a lot of excitement come January interim results with an update on the detector. The market will get excited at this, plus good performance from the rest of the business (which all looks positive) plus I forecast Simon Thompson will include Kromek in his bargain shares edition in feb, given his repeated strong buy, which would have turned into an even better investment than his last review. Given the history of Kromek, not sure if I’ll stay a holder in the very long term. But I think we’ll have an exciting few months/year ahead

I read somewhere a while back about the detector also being used in farming to detect crop pathogens

It’s all looking promising, I’d say there certainly has to be an update on the biological pathogen detector at the interim results on 18th Jan. Kromek were in ‘talks with multiple governments’-ceo, July 2021. So you’d think there will be a bit of positive news here - anything from a firm order to an order of intent from a government.
I’m still gobsmacked at the lack of media attention for the detector. It’s quite an exciting story I’d say. But only just got a decent bit of coverage last week in the FT for the first time.

The wide spectrum detector that detects all strains - even unknown ones was not ready 6months ago and is not ready for release for a little longer to my understanding. The covid specific one was being trialled 6months ago. A biological defence system, which is mentioned in the article, would be the later model out soon.

No announcements of orders yet. Governments are slow beasts with many departments that need to concur on a decision. Health, treasury, other political demands on the cash. The US Congress have only just started discussing budgets required publicly last week. With the current new strain, I’d hope any discussions will have renewed urgency and news ready for the interim results on 18th jan. The U.K. and US governments have funded £1.25m and around $10m to develop the detectors. To develop the detector, market it, manufacture it, finalise it all with the signing of contracts in 6months would be fairly impressive. If they managed that. I’m hopeful by jan 18th the first signed order will have arrived

“In serious discussions with multiple governments,” is what the ceo stated in an interview in July, see link below.

Just one government will alert the market to what’s on offer here and set the share price soaring. Remember, the market cap here was just £60 yesterday

https://www.investorschronicle.co.uk/ideas/2021/07/14/backing-a-tech-winner-in-the-fight-against-covid-19/